Setmelanotide

ID: setmelanotide

Aliases: IMCIVREE, RM-493, BIM-22493

Type: compound

Route/form: subcutaneous injection

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, human_trial, label

Linked sources: 3

Broad outcomes: Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• MC4R agonist
• melanocortin pathway agonist
• appetite and hyperphagia signaling in rare obesity syndromes

Optimization domains

• metabolic
• obesity
• appetite
• rare disease
• genetic obesity
• hypothalamic obesity

Research basis

• Setmelanotide has official label and phase 3 support for specific MC4R-pathway obesity disorders, so it is a real peptide obesity drug rather than a generic fat-loss peptide.
• It is mechanistically useful because it separates rare leptin-melanocortin-pathway obesity from common obesity and from GLP-1/GIP/glucagon agonist biology.
• SC19 and related leads belong downstream of this node as attempts to improve solubility/selectivity and reduce melanocortin off-target liabilities.

Limits, risks, and missing evidence

• The indication is narrow and generally depends on specific genetic or acquired hypothalamic-obesity diagnoses.
• Hyperpigmentation, injection-site reactions, nausea, sexual adverse events, mood monitoring, and cost/access issues matter.
• Approved rare-disease benefit does not imply broad utility for ordinary dieting, bodybuilding cuts, or PED harm reduction.

Risk flags

• approved drug
• peptide
• rare disease context
• mc4r
• hyperpigmentation
• mood monitoring

Linked papers, labels, and reviews

1. DailyMed label: IMCIVREE (setmelanotide) injection
   label / dailymed_imcivree_label
   Current U.S. label for subcutaneous setmelanotide/IMCIVREE; anchors approved indications, warnings, and administration route.
2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency
   human_trial / pubmed_setmelanotide_pomc_lepr_phase3_2020
   Open-label phase 3 POMC/PCSK1 and LEPR deficiency trials with placebo-withdrawal design; supports rare MC4R-pathway obesity use, not common obesity.
3. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alstrom syndrome: a phase 3 trial
   human_rct / doi_setmelanotide_bbs_phase3_2022
   Randomized placebo-controlled phase 3 trial with open-label period for Bardet-Biedl/Alstrom syndrome obesity context.